<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuro Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Neuro-oncology</journal-id><journal-id journal-id-type="publisher-id">neuonc</journal-id><journal-title-group><journal-title>Neuro-Oncology</journal-title></journal-title-group><issn pub-type="ppub">1522-8517</issn><issn pub-type="epub">1523-5866</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31613963</article-id><article-id pub-id-type="pmc">6954395</article-id><article-id pub-id-type="doi">10.1093/neuonc/noz192</article-id><article-id pub-id-type="publisher-id">noz192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Pediatric high-grade glioma resources from the Children&#x02019;s Brain Tumor Tissue Consortium</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ijaz</surname><given-names>Heba</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Koptyra</surname><given-names>Mateusz</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Gaonkar</surname><given-names>Krutika S</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Rokita</surname><given-names>Jo Lynne</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Baubet</surname><given-names>Valerie P</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Tauhid</surname><given-names>Lamiya</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Yuankun</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopez</surname><given-names>Gonzalo</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Diskin</surname><given-names>Sharon J</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0004">4</xref><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Vaksman</surname><given-names>Zalman</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><collab>Children&#x02019;s Brain Tumor Tissue Consortium</collab></contrib><contrib contrib-type="author"><name><surname>Mason</surname><given-names>Jennifer L</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Appert</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Lilly</surname><given-names>Jena</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Lulla</surname><given-names>Rishi</given-names></name><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>De Raedt</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Heath</surname><given-names>Allison P</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Felmeister</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Raman</surname><given-names>Pichai</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Nazarian</surname><given-names>Javad</given-names></name><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Santi</surname><given-names>Maria Rita</given-names></name><xref ref-type="aff" rid="AF0006">6</xref><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Storm</surname><given-names>Phillip B</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref><xref ref-type="aff" rid="AF0005">5</xref><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Resnick</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Waanders</surname><given-names>Angela J</given-names></name><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Cole</surname><given-names>Kristina A</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0007">7</xref><xref ref-type="corresp" rid="c1"/><!--<email>colek@email.chop.edu</email>--></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>Division of Oncology, Department of Pediatrics, Children&#x02019;s Hospital of Philadelphia (CHOP)</institution> Philadelphia, Pennsylvania</aff><aff id="AF0002"><label>2</label>
<institution>The Center for Data Driven Discovery in Biomedicine, CHOP</institution>, Philadelphia, Pennsylvania</aff><aff id="AF0003"><label>3</label>
<institution>The Children&#x02019;s Brain Tumor Tissue Consortium, Operations Center at CHOP</institution>, Philadelphia, Pennsylvania</aff><aff id="AF0004"><label>4</label>
<institution>Department of Biomedical and Health Informatics, CHOP</institution>, Philadelphia, Pennsylvania</aff><aff id="AF0005"><label>5</label>
<institution>Department of Neurosurgery, CHOP</institution>, Philadelphia, Pennsylvania</aff><aff id="AF0006"><label>6</label>
<institution>Department of Pathology, CHOP</institution>, Philadelphia, Pennsylvania</aff><aff id="AF0007"><label>7</label>
<institution>The Perelman School of Medicine, University of Pennsylvania</institution>, Philadelphia, Pennsylvania</aff><aff id="AF0008"><label>8</label>
<institution>Division of Hematology/Oncology, Hasbro Children&#x02019;s Hospital, Department of Pediatrics, The Warren Alpert School of Brown University</institution>, Providence, Rhode Island</aff><aff id="AF0009"><label>9</label>
<institution>Children&#x02019;s Research Institute, Children&#x02019;s National Medical Center, School of Medicine and Health Sciences, George Washington University</institution>, Washington, DC</aff><aff id="AF0010"><label>10</label>
<institution>Division of Hematology, Oncology, and Stem Cell Transplant, Ann &#x00026; Robert H Lurie Children&#x02019;s Hospital of Chicago, Department of Pediatrics, Feinberg School of Medicine Northwestern University</institution>, Chicago, Illinois</aff><author-notes><corresp id="c1"><bold>Corresponding Author:</bold> Kristina A. Cole, M.D., Ph.D. Division of Oncology, Children&#x02019;s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (<email>colek@email.chop.edu</email>).</corresp><fn id="fn-0001"><p>Contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2020</year></pub-date><pub-date pub-type="epub" iso-8601-date="2019-10-15"><day>15</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>10</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>22</volume><issue>1</issue><fpage>163</fpage><lpage>165</lpage><history><date date-type="corrected-typeset"><day>27</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.</copyright-statement><copyright-year>2019</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="noz192.pdf"/><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">CBTTC</named-content></funding-source><award-id>U2C CA233285</award-id></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Human Tumor Atlas Network</named-content></funding-source><award-id>U2C CA233285</award-id></award-group></funding-group><counts><page-count count="3"/></counts></article-meta></front><body><p>Pediatric high-grade gliomas (pHGGs) are a leading cause of pediatric cancer death but are genomically and spatially distinct.<sup><xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref></sup> In this report we describe the generation and characterization of pHGG reagents with linked genomic and longitudinal clinical data freely available to the community to accelerate pHGG research.<sup><xref rid="CIT0003" ref-type="bibr">3</xref></sup></p><p>The pHGG biospecimen collection, annotation, genomic sequencing, and cell line generation were coordinated by the Children&#x02019;s Brain Tumor Tissue Consortium (CBTTC) (<ext-link ext-link-type="uri" xlink:href="https://cbttc.org">https://cbttc.org</ext-link>), which is an international, collaborative, multi-institutional research program dedicated to the study of childhood brain tumors. After project proposal approval, the specimens are delivered to investigators while CBTTC data are available for viewing and download from the Gabriella Miller Kids First Data Resource Center (KF-DRC, <ext-link ext-link-type="uri" xlink:href="https://kidsfirstdrc.org">https://kidsfirstdrc.org</ext-link>) or as processed data in PedcBioPortal (<ext-link ext-link-type="uri" xlink:href="https://pedcbioportal.org">https://pedcbioportal.org</ext-link>). All subjects consented to tissue and data collection through CBTTC Institutional Review Board&#x02013;approved protocols. The KF-DRC is recognized as a National Institutes of Health Trusted Partner for data sharing protections.</p><p>The CBTTC cohort of pHGG primary tumors represents the spectrum of disease. The clinical covariates, genomics, and biospecimens of the pHGG set in this study are shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. The cohort with tumor whole genome sequencing represents 73 participants. Tumors were from participants with a median age of 9 years at diagnosis and 55% were female. Sixty percent were from initial or diagnostic specimens and 46% were from a hemispheric location. Analysis of a selected set of recurrently mutated pHGG genes was of an expected distribution with 47% <italic>TP53</italic>, 36% <italic>H3.3</italic>, 24% <italic>ATRX</italic>, and 7% <italic>BRAF</italic> V600E variants.<sup><xref rid="CIT0002" ref-type="bibr">2</xref></sup> Tumors had mutually exclusive <italic>H3.3</italic> G34 and K27M mutations and co-occurring mutations of <italic>ATRX</italic> with H3.3 G34R or <italic>NF1</italic>.<sup><xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref></sup> Seven participants&#x02019; tumors demonstrated features of hypermutation with somatic and/or germline mismatch repair deficiency.<sup><xref rid="CIT0006" ref-type="bibr">6</xref></sup></p><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>The CBTTC pHGG cohort. OncoPrint of the clinical covariates, genomics, and resources of the pHGG cohort. dx = diagnosis; recc = recurrence; NGS = next generation sequencing of cell lines.</p></caption><graphic xlink:href="noz192f0001"/></fig><p>At the time of study initiation, the CBTTC biorepository had 37 pHGG tumor tissues stored in freezing media that were dissociated and cultured with 4 different culturing conditions. At least one culture grew from 23/37 (62%) dissociation events from 23/73 (31%) patients in our cohort. Patient derived cell line information including prior patient therapy, culture, and growing conditions, including orthotopic xenografts, doubling times, and validation status are described elsewhere.<sup><xref rid="CIT0003" ref-type="bibr">3</xref></sup> The cell line panel represents the spectrum of pHGG genomics with 8 unique patient cell lines with <italic>H3.3</italic> mutations (35%), 6 with <italic>TP53</italic> mutations (26%), 1 with a <italic>BRAF</italic> V600E mutation, and 1 with a <italic>KRAS</italic> Q61H mutation. Three patient cell lines were derived from tumors with mismatch repair deficiency and hypermutation.</p><p>For each of the tumors in the CBTTC there are additional banked biospecimens including tumor tissue, tumor in freezing media, blood, plasma, cerebrospinal fluid, and both tumor and blood derived nucleic acids (<ext-link ext-link-type="uri" xlink:href="https://cbttc.org">https://cbttc.org</ext-link>). Of the pHGG cohort in this study, 36 patient tumors are also available on a tissue microarray. This valuable resource will enable researchers to examine the tumor microenvironment, discover cell surface immunotherapy target proteins, or perform validation studies of the corresponding proteomic dataset. Finally, to facilitate integrative studies, most of the tumors in the pHGG set have corresponding redacted operative reports and pathology and radiology reports, along with the relevant MRI images and histology slides. <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 1</xref> shows reagents for patient PT_9BZETMOM (7316-158 and 7316-5317), whose diagnosis and relapse tumors have the rare H3.3 G34R mutation.</p><p>In summary, the CBTTC with its member institutions, donors, patients, and families has developed an infrastructure to support pHGG research for both large genomic projects and individual laboratories. The CBTTC pHGG patient tumors and associated datasets are expected to increase, which when integrated with adult cancer and other disease sets promise to advance discoveries and hope of effective therapies for this devastating disease.</p><sec id="s0100"><title>Funding</title><p>This work was supported by CBTTC Foundation Partners: <ext-link ext-link-type="uri" xlink:href="https://cbttc.org/partnerships/">https://cbttc.org/partnerships/</ext-link></p><p>This work is supported by the Human Tumor Atlas Network, grant U2C CA233285.</p><p>
<bold>Conflict of interest statement.</bold> None.</p><p>
<bold>CBTTC Member Institutions. </bold> Ann &#x00026; Robert H. Lurie Children&#x02019;s Hospital of Chicago; Children&#x02019;s Hospital of Philadelphia; Children&#x02019;s National Health System; Seattle Children&#x02019;s; Stanford University/Lucile Packard Children&#x02019;s Hospital; University of California San Francisco Benioff Children&#x02019;s Hospital; UPMC Children&#x02019;s Hospital of Pittsburgh; Weill Cornell Medicine Pediatric Brain and Spine Center.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>noz192_suppl_Supplementary_Material</label><media xlink:href="noz192_suppl_supplementary_material.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list id="r1"><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Karajannis</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>DTW</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Pediatric high-grade glioma: biologically and clinically in need of new thinking</article-title>. <source>Neuro Oncol.</source><year>2017</year>;<volume>19</volume>(<issue>2</issue>):<fpage>153</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">27282398</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Burford</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma</article-title>. <source>Cancer Cell</source>. <year>2017</year>;<volume>32</volume>(<issue>4</issue>):<fpage>520</fpage>&#x02013;<lpage>537 e525</lpage>.<pub-id pub-id-type="pmid">28966033</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ijaz</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Koptyra</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gaonkar</surname><given-names>KS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pediatric high grade glioma resources from the Children&#x02019;s Brain Tumor Tissue Consortium (CBTTC) and Pediatric Brain Tumor Atlas (PBTA)</article-title>. <source>bioRxiv</source>. <year>2019</year>. doi:10.1101/656587.</mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>D&#x02019;Angelo</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ceccarelli</surname><given-names>M</given-names></name></person-group>, Tala, <etal>et al.</etal><article-title>The molecular landscape of glioma in patients with neurofibromatosis 1</article-title>. <source>Nat Med.</source><year>2019</year>;<volume>25</volume>(<issue>1</issue>):<fpage>176</fpage>&#x02013;<lpage>187</lpage>.<pub-id pub-id-type="pmid">30531922</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Korshunov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Capper</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Reuss</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity</article-title>. <source>Acta Neuropathol.</source><year>2016</year>;<volume>131</volume>(<issue>1</issue>):<fpage>137</fpage>&#x02013;<lpage>146</lpage>.<pub-id pub-id-type="pmid">26482474</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Light</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Fabrizio</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comprehensive analysis of hypermutation in human cancer</article-title>. <source>Cell</source>. <year>2017</year>;<volume>171</volume>(<issue>5</issue>):<fpage>1042</fpage>&#x02013;<lpage>1056 e1010</lpage>.<pub-id pub-id-type="pmid">29056344</pub-id></mixed-citation></ref></ref-list></back></article>